[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Esperion Theraptc (ESPR)

Esperion Theraptc (ESPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 805,762
  • Shares Outstanding, K 257,432
  • Annual Sales, $ 403,140 K
  • Annual Income, $ -22,680 K
  • EBIT $ 76 M
  • EBITDA $ 79 M
  • 60-Month Beta 0.91
  • Price/Sales 2.00
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 119.57% (+10.22%)
  • Historical Volatility 127.95%
  • IV Percentile 64%
  • IV Rank 37.09%
  • IV High 287.13% on 02/23/26
  • IV Low 20.76% on 05/15/26
  • Expected Move (DTE 17) 0.09 (2.72%)
  • Put/Call Vol Ratio 0.47
  • Today's Volume 469
  • Volume Avg (30-Day) 2,401
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 93,107
  • Open Int (30-Day) 91,827
  • Expected Range 3.05 to 3.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.02
  • Number of Estimates 3
  • High Estimate $0.02
  • Low Estimate $-0.06
  • Prior Year $-0.02
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.10 +1.13%
on 05/04/26
3.18 -1.42%
on 05/06/26
+0.03 (+0.80%)
since 05/01/26
3-Month
1.80 +74.17%
on 04/29/26
3.36 -6.56%
on 03/02/26
-0.21 (-6.42%)
since 02/27/26
52-Week
0.85 +268.82%
on 06/02/25
4.18 -24.91%
on 01/08/26
+2.29 (+268.91%)
since 05/30/25

Most Recent Stories

More News
Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026

– Bempedoic Acid Lowered LDL-C and Was Well Tolerated in Children Aged 6-17 Years – – A Secondary Analysis of CLEAR Outcomes Reports on Patient Factors Associated With 30% or Greater Reduction...

ESPR : 3.13 (unch)
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., May 14, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 12 2026, the Company granted 23 new employees 260,000 restricted stock units (RSUs) under Esperion’s...

ESPR : 3.13 (unch)
Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026

–  Presentations Examine Findings From the Pediatric Phase 2 Study, As Well As Factors Associated With Enhanced LDL-C Reductions in Adult Patients Enrolled in Clear Outcomes – – Pediatric...

ESPR : 3.13 (unch)
Esperion's Post-Acquisition Quarter Tests Whether Integration Pace Matches Revenue Momentum

Barchart Research What to Expect from ESPR Earnings ESPR Generated May 6, 2026 Current Price $3.15 EPS Estimate $$-0.04 Consensus Rating Hold Average Move 9.90% Esperion's Post-Acquisition Quarter Tests...

ESPR : 3.13 (unch)
SHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--ESPR, SILA, CRBG, and EQH

NEW YORK , May 6, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders...

ESPR : 3.13 (unch)
CRBG : 26.75 (-0.93%)
EQH : 40.92 (-0.32%)
SILA : 30.24 (-0.02%)
Are ESPR, GBTG, MDV, ACR Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

ESPR : 3.13 (unch)
ACR : 20.32 (-0.39%)
MDV : 17.88 (-1.54%)
GBTG : 9.34 (unch)
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Esperion Therapeutics...

ESPR : 3.13 (unch)
Shareholder Alert: Ademi LLP investigates whether Esperion Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE , May 1, 2026 /PRNewswire/ -- Ademi LLP is investigating Esperion (NASDAQ: ESPR) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction...

ESPR : 3.13 (unch)
ESPR Stock Alert: Halper Sadeh LLC is Investigating Whether Esperion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that...

ESPR : 3.13 (unch)
Esperion to be Acquired by ARCHIMED

Esperion shareholders to receive $3.16 per share in cash at closing, plus the right to participate in up to $100 million in aggregate contingent milestone payments Represents total equity value of...

ESPR : 3.13 (unch)

Business Summary

Esperion Therapeutics, Inc. is a pharmaceutical company focused on the development of oral lipid-management treatments for cardiovascular diseases caused by elevated levels of LDL-C (bad cholesterol).

See More

Key Turning Points

3rd Resistance Point 3.16
2nd Resistance Point 3.15
1st Resistance Point 3.14
Last Price 3.13
1st Support Level 3.12
2nd Support Level 3.11
3rd Support Level 3.10

See More

52-Week High 4.18
Last Price 3.13
Fibonacci 61.8% 2.90
Fibonacci 50% 2.51
Fibonacci 38.2% 2.12
52-Week Low 0.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.